The Impact Of Allogeneic Hematopoietic Stem Cell Transplantation In Children And Adolescents With Recurring Hodgkin'S Lymphoma: An Ebmt Study On 151 Patients

Background: Allogeneic hematopoietic stem cell transplantation (HSCT) has become a therapeutic option for patients with recurring Hodgkin's lymphoma (HL). Standardized inclusion criteria, the optimal time point and the type of conditioning regimen have, however, not been clarified yet. Moreover, high treatment related mortality (TRM) has hampered the widespread use of this procedure. Only few data are available on the impact of allogeneic HSCT in pediatric and adolescent patients.